02/02/2025
UB-312: A Potential Breakthrough Vaccine for Parkinson’s Disease
UB-312 is a synthetic peptide vaccine developed by the U.S. biotechnology company Vaxxinity. It aims to induce the immune system to produce antibodies targeting α-synuclein (α-syn) aggregates, which accumulate in the brain and contribute to Parkinson’s disease (PD) and other synucleinopathies. By reducing these toxic protein deposits, UB-312 could become a disease-modifying therapy.
---
Clinical Trial Progress
Phase 1 Clinical Trial:
UB-312’s Phase 1 clinical trial was divided into two parts:
Part A:
Involved 50 healthy volunteers aged 40 to 85, who received different doses of UB-312 or a placebo. The results showed that UB-312 was safe and well-tolerated in healthy individuals. Moreover, it successfully induced the production of anti-α-syn antibodies, which were detected in both serum and cerebrospinal fluid (CSF).
Part B:
Included 20 early-stage Parkinson’s patients (Hoehn & Yahr stage ≤ III), who received two different doses of UB-312 or a placebo. After 20 weeks of treatment and 24 weeks of observation, results showed that 92% (12 out of 13) of patients who received UB-312 developed anti-α-syn antibodies. UB-312 remained safe and well-tolerated throughout the trial.
(Source: Vaxxinity Official Site)
---
Exploratory Studies:
In collaboration with the Michael J. Fox Foundation, Mayo Clinic, and UTHealth Houston, researchers used protein misfolding cyclic amplification (PMCA) to evaluate UB-312’s ability to target α-syn aggregates.
Key Findings:
Significant reduction of α-syn aggregates in CSF samples of UB-312-treated patients.
Improved motor function in daily activities.
(Source: Vaxxinity)
---
Future Prospects
The Phase 1 clinical trial results are promising, showing strong safety, immunogenicity, and target engagement.
UB-312 has now entered Phase 2 clinical trials and has the potential to become a disease-modifying therapy for Parkinson’s.
(Source: Alzforum)
---
Is This a Cure for Parkinson’s?
While UB-312 represents a major breakthrough, it is still in clinical trial stages and not yet widely available. Future studies are required to confirm its long-term efficacy and safety. If successful, Parkinson’s patients might only need vaccine injections to manage or even halt disease progression in the future.
